Neaton immediately called Baron, who was conducting the trial with a grant from Merck, and explained the problem.
FOR MORE INFORMATION:  Less than a week after Merck & Co. yanked its popular Vioxx arthritis drug off the market, the New England Journal of Medicine voiced strong concerns Wednesday about the safety of Pfizer's bestselling Celebrex.
The FDA's opportunity to act independently on Vioxx ended on Sept. 27, when the fax came from Merck asking for an urgent meeting with senior officials.
